Cargando…
Metformin in the Treatment of Amisulpride-Induced Hyperprolactinemia: A Clinical Trial
OBJECTIVE: To evaluate the efficacy and safety of metformin in the treatment of amisulpride-induced hyperprolactinemia. METHODS: A total of 86 schizophrenic patients who developed hyperprolactinemia after taking amisulpride were screened and randomly assigned to the metformin group (42 patients) and...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9205636/ https://www.ncbi.nlm.nih.gov/pubmed/35721320 http://dx.doi.org/10.3389/fnmol.2022.892477 |
_version_ | 1784729170930040832 |
---|---|
author | Zhu, Cuifang Li, Ruofan Ju, Mingliang Xiao, Xudong Yuan, Ti-Fei Jin, Zhixing Zhao, Jing |
author_facet | Zhu, Cuifang Li, Ruofan Ju, Mingliang Xiao, Xudong Yuan, Ti-Fei Jin, Zhixing Zhao, Jing |
author_sort | Zhu, Cuifang |
collection | PubMed |
description | OBJECTIVE: To evaluate the efficacy and safety of metformin in the treatment of amisulpride-induced hyperprolactinemia. METHODS: A total of 86 schizophrenic patients who developed hyperprolactinemia after taking amisulpride were screened and randomly assigned to the metformin group (42 patients) and placebo group (44 patients) and followed up for eight weeks. The patients’ serum prolactin levels, blood glucose and lipids were measured at the baseline and the end of the intervention. The treatment emergent symptom scale (TESS) was also assessed. RESULTS: After eight weeks of intervention, serum prolactin levels in the metformin group decreased from (1737.360 ± 626.918) mIU/L at baseline to (1618.625 ± 640.865) mIU/L, whereas serum prolactin levels in the placebo group increased from (2676.470 ± 1269.234) mIU/L at baseline to (2860.933 ± 1317.376) mIU/L. There was a significant difference in prolactin changes (F(covariance) = 9.982, P = 0.002) between the two groups. There was no significant difference in the incidence of adverse drug reactions (P > 0.05) between the two groups. CONCLUSION: Metformin is able to improve amisulpride-induced hyperprolactinemia with its safety. |
format | Online Article Text |
id | pubmed-9205636 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92056362022-06-18 Metformin in the Treatment of Amisulpride-Induced Hyperprolactinemia: A Clinical Trial Zhu, Cuifang Li, Ruofan Ju, Mingliang Xiao, Xudong Yuan, Ti-Fei Jin, Zhixing Zhao, Jing Front Mol Neurosci Neuroscience OBJECTIVE: To evaluate the efficacy and safety of metformin in the treatment of amisulpride-induced hyperprolactinemia. METHODS: A total of 86 schizophrenic patients who developed hyperprolactinemia after taking amisulpride were screened and randomly assigned to the metformin group (42 patients) and placebo group (44 patients) and followed up for eight weeks. The patients’ serum prolactin levels, blood glucose and lipids were measured at the baseline and the end of the intervention. The treatment emergent symptom scale (TESS) was also assessed. RESULTS: After eight weeks of intervention, serum prolactin levels in the metformin group decreased from (1737.360 ± 626.918) mIU/L at baseline to (1618.625 ± 640.865) mIU/L, whereas serum prolactin levels in the placebo group increased from (2676.470 ± 1269.234) mIU/L at baseline to (2860.933 ± 1317.376) mIU/L. There was a significant difference in prolactin changes (F(covariance) = 9.982, P = 0.002) between the two groups. There was no significant difference in the incidence of adverse drug reactions (P > 0.05) between the two groups. CONCLUSION: Metformin is able to improve amisulpride-induced hyperprolactinemia with its safety. Frontiers Media S.A. 2022-05-26 /pmc/articles/PMC9205636/ /pubmed/35721320 http://dx.doi.org/10.3389/fnmol.2022.892477 Text en Copyright © 2022 Zhu, Li, Ju, Xiao, Yuan, Jin and Zhao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neuroscience Zhu, Cuifang Li, Ruofan Ju, Mingliang Xiao, Xudong Yuan, Ti-Fei Jin, Zhixing Zhao, Jing Metformin in the Treatment of Amisulpride-Induced Hyperprolactinemia: A Clinical Trial |
title | Metformin in the Treatment of Amisulpride-Induced Hyperprolactinemia: A Clinical Trial |
title_full | Metformin in the Treatment of Amisulpride-Induced Hyperprolactinemia: A Clinical Trial |
title_fullStr | Metformin in the Treatment of Amisulpride-Induced Hyperprolactinemia: A Clinical Trial |
title_full_unstemmed | Metformin in the Treatment of Amisulpride-Induced Hyperprolactinemia: A Clinical Trial |
title_short | Metformin in the Treatment of Amisulpride-Induced Hyperprolactinemia: A Clinical Trial |
title_sort | metformin in the treatment of amisulpride-induced hyperprolactinemia: a clinical trial |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9205636/ https://www.ncbi.nlm.nih.gov/pubmed/35721320 http://dx.doi.org/10.3389/fnmol.2022.892477 |
work_keys_str_mv | AT zhucuifang metformininthetreatmentofamisulprideinducedhyperprolactinemiaaclinicaltrial AT liruofan metformininthetreatmentofamisulprideinducedhyperprolactinemiaaclinicaltrial AT jumingliang metformininthetreatmentofamisulprideinducedhyperprolactinemiaaclinicaltrial AT xiaoxudong metformininthetreatmentofamisulprideinducedhyperprolactinemiaaclinicaltrial AT yuantifei metformininthetreatmentofamisulprideinducedhyperprolactinemiaaclinicaltrial AT jinzhixing metformininthetreatmentofamisulprideinducedhyperprolactinemiaaclinicaltrial AT zhaojing metformininthetreatmentofamisulprideinducedhyperprolactinemiaaclinicaltrial |